Javelin Biotech’s Post

Now available – RFdiffusion 2.0 NIM This #NVIDIANIM enables researchers to efficiently design protein therapeutic candidates 1.9x faster due to accelerations in the inference engine, making their preclinical research smarter and less expensive. Get started today. #drugdiscovery

Preclinical study showed that microglia-mediated neuron death requires TNF and is exacerbated by mutant Huntingtin: https://lnkd.in/dPD_RUMV  #Huntington #Microglia #PharmacolRes #openaccess #Research 

Revolutionizing Target Discovery and Precision Medicine with Cell-Based Phage Display! Unlocking the potential of novel therapeutics and diagnostics demands precise targeting of disease-specific molecules. Cell-based phage display offers a powerful solution, enabling the identification of high-affinity peptides that bind to targets in their natural cellular context. This innovative technology streamlines drug discovery, diagnostics development, and fundamental research across various therapeutic areas. Read our latest blog post to learn how Biosynth is leveraging cell-based phage display to accelerate the development of targeted therapies and precision medicine tools. https://lnkd.in/ese4CMfW #phageDisplay #biotechnology #drugdiscovery #diagnostics #precisionmedicine #innovation #Biosynth

𝗙𝗿𝗼𝗺 𝟮𝗗 𝘁𝗼 𝟯𝗗: 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗠𝗼𝗱𝗲𝗹𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 https://lnkd.in/dfRtSXjn 👨🔬 "𝘚𝘵𝘢𝘳𝘵𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘴𝘪𝘮𝘱𝘭𝘦 𝟤𝘋 𝘢𝘴𝘴𝘢𝘺𝘴 𝘧𝘰𝘳 𝘳𝘢𝘱𝘪𝘥 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘸𝘦 𝘵𝘩𝘦𝘯 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯 𝘵𝘰 𝘮𝘰𝘳𝘦 𝘤𝘰𝘮𝘱𝘭𝘦𝘹 𝟥𝘋 𝘮𝘰𝘥𝘦𝘭𝘴 𝘵𝘰 𝘥𝘦𝘦𝘱𝘦𝘯 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘯𝘥 𝘦𝘯𝘩𝘢𝘯𝘤𝘦 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺." ✨ 🎥 Check out this short video by @𝗘𝘂𝗴𝗲𝗻𝗶𝗼 𝗙𝗮𝘃𝗮 from German Center for Neurodegenerative Diseases (DZNE) sharing some great practical insights into recent developments in #neuroscience and early drug discovery. Key Points: 1. 2D Models: Quick and stable for initial screening. 2. 3D Models: Provide advanced biological insights but are more complex. 3. Sequential Approach: Begin with simple models, then introduce complexity. 4. Tissue-like Models: Useful but technically challenging for screening. 5. Oncology: Evidence of 3D model utility despite implementation challenges. Thank you so much for your interest. 🔜 Stay Tuned: #CELLIMATALKS will continue for more on #drugdiscovery, #highcontentimaging, and #bigdata applications in #pharmaceuticalresearch. 🔗 If you'd like to delve deeper into this topic with Eugenio, you can listen to the full interview here: https://lnkd.in/dek8aAqU #lifesciences #CellPainting #Healthcare CELLIMA Scientific Service GmbH

Cellular in vitro models are crucial in preclinical research for understanding the pathologies and development of new drugs. However, due to the complex nature of the human body, obtaining accurate cell models can be difficult.   Tebubio, our European distributor, is delivering a webinar on the challenges of in vitro models, exploring the advantages of consolidating biological sample sourcing with a single, reliable partner, and sharing insights into the comprehensive solutions available for cultivating pertinent cellular models.   📅Tuesday 25th June 🕐10:00am BST | 11:00am CEST 💻Register here: https://rb.gy/3j3zel   #CellularResearch #InVitroModels #ResearchEfficiency

Discover how organoids bridge the gap between the lab and clinic Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM BST to learn more about how patient-derived organoids are revolutionising drug discovery. https://lnkd.in/eEC865ka #Organoids #DrugDiscovery #LifeSciences HUB Organoids

A systematic review of the local field potential adaptations during conditioned place preference task in preclinical studies https://lnkd.in/ey3zFxmM

In the hallowed halls of the Princeton Hotel Crown Plaza, amidst the ongoing symposium of the esteemed Alcor 7th Drug Discovery Platform, Dr. Ravi Kumar, Founder & Chief Scientific Officer of Immunocure Inc, graces the stage with his profound insights. Topic: Illuminating AI-Driven Drug Discovery: AxDrug for Automated Lead Generation and Optimization Dr. Ravi Kumar Muttineni, the luminary behind Immunocure Discovery Solutions, stands as a beacon of innovation in the realm of early drug discovery. Through their avant-garde Contract Research Organization (CRO), empowered by the proprietary AI platform, AxDrug, Immunocure seamlessly integrates cutting-edge computational chemistry tools and a state-of-the-art synthetic chemistry lab. Pioneering advancements in lead molecule delivery, targeted protein degraders (TPDs), protein designing, and antibody engineering, Immunocure sets a new benchmark for innovation. Join us as we embark on a journey to redefine possibilities and unlock the latent potential of tomorrow's therapeutics alongside Dr. Ravi Kumar. This is an invitation to participate in the shaping of the future of drug discovery, where every molecule holds the promise of transformative impact. #ADDP2024 #7thADDP #Alcordrugdiscoveryplatform #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI #ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug #alcordrug #alcordiscovery #addp2024

Stop by the BioModels table today to learn more about how we can support your preclinical study needs!

In drug discovery, preclinical & clinical development, it's important to get the maximum information from your precious samples. Whether they're fresh, fixed or archived tissues, expensive model organisms, or critical patient biopsies. It's amazing to see the work being done using 10x Genomics single cell and spatial technologies in BioPharma to maximise information gained throughout devlopment, in order minimise late stage failures during clinical trials and increase drug success rates. #drugdevelopment #drugdiscovery #clinicaltrials